Balanced news tone
News Sentiment
KPRX sentiment intelligence
Kiora Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
53
Balanced news tone
45 relevant articles
Price is moving more forcefully than the current news tone suggests.
79/100 classification confidence.
directly relevant articles
high-authority source matches
-4.6% over one week, -1.6% over four weeks, trend active, and below fair value.
Enterprise value to revenue forward of Kiora Pharmaceuticals, Inc. – LS:A40EG5
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
79/100 classification
One-week reaction
-4.6%
Price reacting lower
Trend fit
Trend active
-1.6% over four weeks
Fair value
-30.9%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
7
Neutral
33
Negative
5
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
TradingView
Direct company coverage
Enterprise value to revenue forward of Kiora Pharmaceuticals, Inc. – LS:A40EG5
This article focuses on the enterprise value to revenue forward for Kiora Pharmaceuticals, Inc. (LS:A40EG5). It presents no specific data but indicates where one might find such financial information and related news on the TradingView platform.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 Jul 2026 02:40
- Source
- TradingView
timothysykes.com
Direct company coverage
Kiora Pharmaceuticals Inc. (KPRX) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live quotes and charts for Kiora Pharmaceuticals Inc. (KPRX) stock. It includes current stock price, basic charting options, and a note indicating no analyst ratings or earnings information currently available. The article also contains extensive disclaimers ab
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 10 Jul 2026 00:43
- Source
- timothysykes.com
TradingView
Direct company coverage
Enterprise value to revenue forward of Kiora Pharmaceuticals, Inc. – GETTEX:7EY
This article provides financial information for Kiora Pharmaceuticals, Inc. (GETTEX:7EY), specifically focusing on its enterprise value to revenue forward. It appears to be a stub or a data point from a financial platform like TradingView, indicating no extensive textual analysis
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 Jul 2026 12:11
- Source
- TradingView
TradingView
Direct company coverage
Price to book forward of Kiora Pharmaceuticals, Inc. – NASDAQ:KPRX
The article focuses on Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) and presents its "Price to book forward" financial metric. It appears to be a stub or a section of a larger financial data page on TradingView, indicating that the value for this specific metric is missing or not pr
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Jul 2026 16:40
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBIT forward of Kiora Pharmaceuticals, Inc. – NASDAQ:KPRX
This article provides financial information for Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) on TradingView, specifically focusing on its enterprise value to forward EBIT. The content indicates that the market for KPRX was closed with no trades at the time of publication. It highlig
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Jul 2026 13:11
- Source
- TradingView
Finviz
Direct company coverage
KPRX - Kiora Pharmaceuticals Inc Latest SEC Filings
This article provides the latest SEC filing information and detailed financial data for Kiora Pharmaceuticals Inc. (KPRX). Key metrics include its market capitalization, enterprise value, income, sales, per-share values, dividend information, and various financial ratios, alongsi
- Tone
- Negative 39/100
- Event
- Capital return
- Published
- 05 Jul 2026 04:41
- Source
- Finviz
Investing.com India
Direct company coverage
Form 4 Kiora Pharmaceuticals Inc For: 2 July By Investing.com
This article announces the filing of Form 4 for Kiora Pharmaceuticals Inc on July 2nd. It provides key financial data for several indices, commodities, and individual stocks, along with various market news headlines. The content also features sections on trending stocks, market m
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jul 2026 02:22
- Source
- Investing.com India
Stock Titan
Direct company coverage
Kiora (NASDAQ: KPRX) CFO uses 911 shares to cover tax obligations
Kiora Pharmaceuticals' CFO, Melissa Tosca, reported a tax-withholding disposition of 911 shares of common stock at $2.66 per share on July 1, 2026. This transaction was to cover tax obligations and not an open-market sale. Following this, Tosca directly holds 26,064 KPRX shares.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 21:10
- Source
- Stock Titan
Stock Titan
Direct company coverage
[Form 4] KIORA PHARMACEUTICALS INC Insider Trading Activity
Kiora Pharmaceuticals' President and CEO, Brian M. Strem, reported a tax-related disposition of 1,869 common shares on July 1, 2026, at a price of $2.66 per share. This transaction was for withholding tax obligations and not an open market sale. Following this adjustment, Strem d
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 21:10
- Source
- Stock Titan
Market source
Direct company coverage
Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
Kiora Pharmaceuticals announced its participation in the Piper Sandler Virtual Ophthalmology Symposium, featuring an investor fireside chat on July 9, 2026. The clinical-stage biotechnology company focuses on developing advanced therapies for retinal diseases, including KIO-301 f
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 18:10
- Source
- Market source
Stock Titan
Direct company coverage
Kiora set for Piper Sandler fireside chat on July 9
Kiora Pharmaceuticals (NASDAQ:KPRX) will participate in an investor fireside chat at the Piper Sandler Virtual Ophthalmology Symposium on Thursday, July 9, 2026, at 2:30 p.m. EDT. The presentation will be webcast live and a replay will be available for 90 days on Kiora's Investor
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 11:12
- Source
- Stock Titan
TradingView
Direct company coverage
Kiora Pharmaceuticals Inc Warrant 2022-27.09.27 on Kiora Pharma A Financial Disclosures & SEC Filings
This page provides access to financial disclosures and SEC filings for Kiora Pharmaceuticals, Inc. (KPHMW), including Forms 10-K, 10-Q, 8-K, and other key documents. The content highlights the company's financial performance, operational updates, clinical trial progress, and corp
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 22:40
- Source
- TradingView
TradingView
Direct company coverage
KPRX Forecast — Price Target — Prediction for 2027
This article provides a price forecast and current statistics for Kiora Pharmaceuticals, Inc. (KPRX). Analysts have set a price target range of $12.00, with varied recommendations for the stock. The article also covers KPRX's current stock price dynamics, historical highs and low
- Tone
- Negative 39/100
- Event
- Guidance
- Published
- 26 Jun 2026 13:10
- Source
- TradingView
TradingView
Direct company coverage
Kiora Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:KPRX)
This article provides an overview of Kiora Pharmaceuticals, Inc. (KPRX) stock, including current price, historical performance, analyst forecasts, and financial estimates. It highlights key financial data, such as market capitalization, earnings per share, and net income, and con
- Tone
- Negative 39/100
- Event
- Earnings
- Published
- 26 Jun 2026 09:11
- Source
- TradingView
TradingView
Direct company coverage
7EY Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Kiora Pharmaceuticals, Inc. (7EY) on the Frankfurt Stock Exchange. It details analyst opinions, past performance data, financial reports, and answers frequently asked questions about the company's stock, including earnings, ne
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 26 Jun 2026 06:10
- Source
- TradingView
TradingKey
Direct company coverage
Kiora Pharmaceuticals Inc (KPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Kiora Pharmaceuticals Inc (KPRX), detailing its price momentum score of 6.44 and its ranking within the Biotechnology & Medical Research industry. It identifies current support and resistance levels at $2.36 and $2.81, respectively, s
- Tone
- Negative 39/100
- Event
- Market update
- Published
- 22 Jun 2026 12:10
- Source
- TradingKey
The Globe and Mail
Direct company coverage
Analysts Are Bullish on Top Healthcare Stocks: Ascentage Pharma Group International (HK:6855), Kiora Pharmaceuticals (KPRX)
The article highlights bullish sentiments from analysts on three healthcare stocks: Ascentage Pharma Group International (HK:6855), Kiora Pharmaceuticals (KPRX), and Luye Pharma Group (LYPHF). Guoyuan Securities (HK) Ltd maintained a Buy rating for Ascentage Pharma with a HK$43.7
- Tone
- Positive 86/100
- Event
- Analyst action
- Published
- 21 Jun 2026 09:16
- Source
- The Globe and Mail
Yahoo! Finance Canada
Direct company coverage
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
Kiora Pharmaceuticals announced preclinical data showing that its ion channel modulator, KIO-300, significantly suppressed seizure activity in an ex vivo temporal lobe epilepsy model. These findings, presented at the Epilepsy Foundation Pipeline Conference, suggest the platform h
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 19 Jun 2026 12:10
- Source
- Yahoo! Finance Canada
Stock Titan
Direct company coverage
KPRX SEC Filings - KIORA PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms
This page provides access to KIORA PHARMACEUTICALS (KPRX) SEC filings, including 10-K, 10-Q, and 8-K forms, with AI-generated summaries and sentiment analysis. Recent filings include the Q3 2025 10-Q reporting a small net income and strong liquidity, and several Schedule 13G/A fi
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 19 Jun 2026 11:39
- Source
- Stock Titan
Minichart
Direct company coverage
Kiora Pharmaceuticals’ KIO-300 Shows Significant Seizure Suppression in Preclinical Epilepsy Model, Revealing Potential Beyond Ophthalmology 1 – Minichart
Kiora Pharmaceuticals announced significant preclinical results for KIO-300, demonstrating its ability to suppress seizure activity in an ex vivo temporal lobe epilepsy model. These findings suggest KIO-300, initially developed for retinal diseases, has potential in neurological
- Tone
- Positive 80/100
- Event
- Earnings
- Published
- 18 Jun 2026 15:09
- Source
- Minichart
TradingKey
Direct company coverage
Kiora Pharmaceuticals Inc (KPRX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Kiora Pharmaceuticals Inc (KPRX), outlining its major shareholders, their proportion of holdings, and institutional investment trends. Key shareholders include Adar1 Capital Management LLC and Stonepine Capital Management, LLC, wh
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 14:10
- Source
- TradingKey
Stock Titan
Direct company coverage
Kiora's KIO-300 cut epileptiform activity in epilepsy model
Kiora Pharmaceuticals (NASDAQ: KPRX) announced preclinical data indicating its ion channel modulator, KIO-300, significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy model. These findings were presented at the Epilepsy Found
- Tone
- Positive 81/100
- Event
- Market update
- Published
- 18 Jun 2026 11:09
- Source
- Stock Titan
Stock Titan
Direct company coverage
Kiora Pharmaceuticals (NASDAQ: KPRX) reports KIO-300 epilepsy model data
Kiora Pharmaceuticals announced preclinical data for its ion channel modulator, KIO-300, showing it significantly suppressed seizure activity in an ex vivo temporal lobe epilepsy model. This finding suggests potential applications for KIO-300, the active ingredient in its Phase 2
- Tone
- Positive 74/100
- Event
- Market update
- Published
- 18 Jun 2026 11:09
- Source
- Stock Titan
TradingKey
Direct company coverage
Kiora Pharmaceuticals Inc (KPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates
Kiora Pharmaceuticals Inc (KPRX) has an earnings forecast score of 8.00, ranking 165 out of 389 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $12.00, indicating a significant upside. The company's expected revenue for the next quar
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 18 Jun 2026 10:39
- Source
- TradingKey
TradingKey
Direct company coverage
Kiora Pharmaceuticals Inc (KPRX) Valuation: PE, PB & Fair Value Analysis
The article provides a valuation analysis of Kiora Pharmaceuticals Inc (KPRX), noting its current valuation score is 8.69, ranking 104 out of 388 in its industry. It highlights the company's P/E ratio of -0.97 but also states that data for P/B, P/S, and P/CF ratios have not yet b
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 10:09
- Source
- TradingKey
TradingKey
Direct company coverage
Kiora Pharmaceuticals Inc (KPRX) Institutional Confidence
This article provides details on the institutional confidence score for Kiora Pharmaceuticals Inc (KPRX), which is currently 3.00, unchanged from its previous score. It lists several institutional shareholders and their recent changes in shares held, indicating varying levels of
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:09
- Source
- TradingKey
TradingKey
Direct company coverage
Kiora Pharmaceuticals Inc (KPRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Kiora Pharmaceuticals Inc (KPRX), focusing on business segments and regional contributions. However, it states that relevant data for FY2025 (including Q1, Q2, Q3) and FY2024, FY2021, FY2020, FY2019 have not yet been disclosed by the
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 03:40
- Source
- TradingKey
TradingKey
Direct company coverage
Kiora Pharmaceuticals Inc (KPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides historical dividend and stock split information for Kiora Pharmaceuticals Inc (KPRX). It notes that KPRX has not distributed any dividends over the past five years. The article primarily details multiple stock merger events, specifically 9-to-1 mergers in Ju
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 18 Jun 2026 01:40
- Source
- TradingKey
Stock Titan
Direct company coverage
Kiora Pharmaceuticals (NASDAQ: KPRX) director receives stock options for 25,000 shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jun 2026 07:00
- Source
- Stock Titan